Hey, looks like people are having fun at my expense again. I hope it adds to their day.
For the record...
If I was smart enough to read the Senate version of the bill to find out there was a 12-year grace on biosimilars, why would anyone be so daft to assert that I would have missed the fact it was only on new approvals?
I think biosimilar/biogeneric producers will be to the 2000s what genomics companies were to the 1990s. Those who recognize they are investing in a fad and are accordingly nimble will be able to make a profit. Those who think it is some paradigm shift and a place to make long-term wealth will be disappointed.
Feel free to disagree with me. Better yet, put your anonymous reputations out there and pick a portfolio of biosimilar producers some time this week and update the profit/loss on them once a month. Then, simultaneously place a forecast right now on how much money you think you'll make by this time in 2010 (go ahead and use outperformance relative to an index if you want to correct for macro market issues). That way you'll have two ways to show how stupid I am: (1) How much money you make; and (2) That I was wrong it was just a fad (August 2010 should be enough time to demonstrate that).
As to the rest, anyone who reads our work knows we often admit mistakes. The entire May 2004 issue was a litany of how we missed on Genta. Most of our issues since the FDA turned back Provenge have included items we didn't put together that caused us to be surprised by the FDA's action on DNDN. I'm sorry if I don't fall on my sword publicly enough for the likes of a few anonymous message board posters.
News 
Market Data 
Discover 
